Company intelligence / Profile preview

ASC Biosciences

Las Vegas, Nevada, United States

Ownership: Private
Development stage: Other

Overview

ASC Biosciences developed a proprietary adult stem cell platform for tissue regeneration; its primary clinical-stage program, ASC-OC1 for cartilage regeneration, remained in pre-clinical development as of the latest available reports. No clinical trial results are available and the product has not been approved by the FDA.

Therapeutic areas: RheumatologyOther
Modalities: Stem cell therapyCell therapyBiologic
Industry: Biotech

Partnerships

Catalent (GMP cell manufacturing)Sheridan Law (patent/IP strategy)

Beyond the preview

Go deeper on ASC Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC Biosciences.

Explore the full profile